Clinical Commander

Back to dossier
cardio.acute-hf.thyrotoxicosis.v1PRODUCTION
cardio.acute-hf.thyrotoxicosis.v1

Acute HF — thyrotoxicosis-induced (high-output)

cardiologyacuteadult
Hard-required inputs
0 / 10
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Thyrotoxicosis-induced high-output HF: TSH suppressed + elevated free T4/T3 + HF symptoms; AFib with RVR common precipitant; consider storm if Burch-Wartofsky ≥45; etiology drives definitive therapy

Inputs
1
Actions
0
Advance rule
Set
Advance when

thyrotoxic HF framed

Patient inputs (10)

Older patients have apathetic thyrotoxicosis (subtle presentation) + higher AFib + HF risk; pregnancy alters drug choice (PTU first trimester, methimazole 2nd-3rd)

Prior Graves diagnosis, neck irradiation, recent pregnancy/delivery, amiodarone, contrast exposure, exogenous hormone; etiology guides definitive therapy choice

Baseline LFTs essential before PTU (hepatotoxicity risk including fulminant hepatic failure) + methimazole (cholestasis); also elevated in thyroid storm itself

Baseline before thionamide (agranulocytosis ~0.3%); pregnancy test in reproductive-age women

eGFR for drug dosing; cardiorenal physiology if HF + AKI; baseline for I-131 contraindication assessment

Storm precipitants: surgery, infection, parturition, withdrawal of antithyroid drugs, iodine load (contrast), thyroid manipulation, DKA, MI, trauma — must identify + treat to resolve storm

TSH <0.01 + elevated free T4 and/or T3 confirms thyrotoxicosis; T3 toxicosis if T4 normal but T3 elevated (~5%); subclinical if FT4/T3 normal but TSH suppressed (less HF risk)

AFib in 10-25% of thyrotoxicosis (50%+ in elderly); RVR drives high-output HF decompensation; rule out other arrhythmias (atrial flutter, MAT)

High CO state with normal/elevated EF + dilated atria (often biatrial); LV dysfunction with chronic untreated thyrotoxicosis; rule out underlying valvular disease

Burch-Wartofsky Point Scale: temperature, CNS, GI, HR, HF → ≥45 = thyroid storm; 25-44 = impending; <25 = unlikely; drives ICU + storm protocol

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (4)

4 need judgement
  • informationallife_threateningthyroid_storm_burch_wartofsky_above_45
    Burch-Wartofsky Point Scale ≥45 — fever (>38.9), CNS (agitation/AMS), GI (vomiting/diarrhea/jaundice), HR >130, HF (CHF/Killip), precipitating event present — life-threatening decompensation
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereatrial_fibrillation_with_thyrotoxic_hf
    New AFib with rapid ventricular response (HR >120) + features of thyrotoxic HF (pulmonary edema, peripheral edema, NYHA III-IV) — common decompensation pattern in thyrotoxicosis
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereptu_induced_hepatotoxicity
    LFT elevation >3x baseline OR jaundice in patient on PTU therapy — BLACK BOX warning
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverecontrast_induced_thyrotoxicosis_from_ct_or_angiography
    New thyrotoxicosis within 6-8 weeks of iodinated contrast exposure (CT, angiography, ERCP) — Jod-Basedow phenomenon especially in pre-existing autonomous thyroid disease
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Thyrotoxicosis-induced high-output HF — BB + thionamide + iodine + steroid (in storm) + supportive HF (ATA 2016 PMID 27521067; JCEM 2023 storm; Klein NEJM 2001)
axis: thyrotoxic_high_output_hf_phenotype
Selected axis "Thyrotoxicosis-induced high-output HF — BB + thionamide + iodine + steroid (in storm) + supportive HF (ATA 2016 PMID 27521067; JCEM 2023 storm; Klein NEJM 2001)" by default fallback (first axis)
  • propranolol
    first line
    beta_blocker_nonselective
    40 mg PO q4-6h (titrate to HR <100); IV 0.5-1 mg q5min in severe tachycardia (max 5 mg) • PO/IV • q4-6h titrate
    triggers: thyrotoxicosis_with_hr_above_100, thyroid_storm, afib_rvr_in_thyrotoxicosis
    ATA 2016 — first-line for symptomatic relief + reduces peripheral T4→T3 conversion (unique to nonselective BB at higher doses); PRIMARY benefit even before thionamide takes effect (days-weeks)
    rxcui 8787
  • esmolol
    comorbidity specific
    beta_blocker_short_acting
    500 µg/kg IV bolus then 50-200 µg/kg/min infusion • IV • continuous infusion
    triggers: severe_thyroid_storm_requiring_iv_titration, concern_for_decompensated_lv_dysfunction_needing_titratable_bb
    Titratable IV BB for storm with severe tachycardia or potential decompensation; rapid offset allows reversal if pulmonary edema worsens
    rxcui 49737
  • methimazole
    first line
    thionamide_antithyroid
    20-30 mg PO daily (single or divided dose); 60-80 mg/d in storm • PO • daily or BID-TID in storm
    triggers: thyrotoxicosis_outside_first_trimester_pregnancy
    ATA 2016 first-line outside pregnancy first trimester due to PTU hepatotoxicity; once-daily dosing improves adherence; longer half-life than PTU
    rxcui 6835
  • propylthiouracil_PTU
    comorbidity specific
    thionamide_antithyroid
    100 mg PO q8h (300 mg/d); 200 mg q4h (1200 mg/d) in storm • PO • q8h or more frequent in storm
    triggers: first_trimester_pregnancy, thyroid_storm_for_t4_to_t3_block, methimazole_allergy_or_intolerance
    PTU PREFERRED in first trimester (lower teratogenicity than methimazole) + in storm (more rapidly blocks peripheral T4→T3 conversion); BLACK BOX for hepatotoxicity outside these indications
    rxcui 8794
  • potassium_iodide_lugol_solution
    add on
    iodine_blocking_agent
    Lugol solution 5 drops (250 mg iodine) PO q8h OR SSKI 5 drops PO q8h • PO • q8h × 7-10 d
    triggers: thyroid_storm, pre_thyroidectomy_preparation_in_graves
    ATA 2016 thyroid storm Class I — Wolff-Chaikoff effect blocks hormone release; MUST give ≥1 h AFTER thionamide to prevent escape (substrate for new synthesis); also pre-op prep for thyroidectomy (reduces gland vascularity)
    rxcui 8597
  • hydrocortisone
    add on
    corticosteroid_glucocorticoid
    100 mg IV q8h (300 mg/d total) — also dexamethasone 2 mg IV q6h alternative • IV • q8h
    triggers: thyroid_storm, amiodarone_induced_thyrotoxicosis_type_2
    ATA 2016 storm Class IIa — reduces peripheral T4→T3 conversion + adrenal support (relative adrenal insufficiency in storm); also primary therapy for amiodarone type 2 thyrotoxicosis (destructive thyroiditis)
    rxcui 5492
  • cholestyramine
    add on
    bile_acid_sequestrant
    4 g PO QID • PO • QID
    triggers: severe_thyroid_storm_with_hyperthyroxinemia
    Binds enterohepatic T4 to lower circulating hormone; useful in storm with very high T4 levels; safe + cheap adjunct
    rxcui 2447
  • furosemide
    comorbidity specific
    loop_diuretic
    20-40 mg IV (NOT 80-160 — high-output state with often hyperdynamic SVR) titrate to UOP • IV • q8-12h titrate
    triggers: thyrotoxic_hf_with_pulmonary_edema
    Standard loop for congestion in HF; gentler dosing in high-output failure (less LV systolic dysfunction; over-diuresis worsens hyperdynamic state)
    rxcui 4603
  • apixaban
    comorbidity specific
    doac_factor_xa_direct
    5 mg PO BID (2.5 mg BID if 2 of 3 dose-reduction criteria) • PO • BID
    triggers: afib_with_chads_vasc_above_2_in_thyrotoxicosis
    AFib in thyrotoxicosis is independent stroke risk factor; ACC/AHA 2023 (PMID 38033089) — DOAC preferred over warfarin in non-valvular AFib; apixaban favored in elderly per ARISTOTLE
    rxcui 1364430
  • digoxin
    add on
    cardiac_glycoside
    0.125-0.25 mg PO daily (renal-adjusted; target serum 0.5-0.9 ng/mL) • PO • daily
    triggers: afib_rvr_inadequately_controlled_with_bb_alone_in_thyrotoxic_hf
    Add-on rate control if BB insufficient (thyrotoxicosis often resistant to digoxin alone — increased renal clearance + decreased receptor affinity); narrow therapeutic window
    rxcui 3407

outpatient playbook — drug actions (3)

  1. 1. maintenance methimazole 5-10 mg/d × 12-18 mo for Graves trial of medical
    rxcui 6694
    5-10 mg PO daily • PO • daily
    trigger: Graves disease + opted for medical trial
    ATA 2016 — 12-18 mo medical trial; ~30-40% remission rate
  2. 2. definitive therapy planning — RAI (I-131) OR thyroidectomy when euthyroid
    rxcui 1546394
    RAI 5-15 mCi (calculated by uptake + gland size) • PO • single dose
    trigger: Graves not in remission OR toxic nodular disease OR patient preference
    ATA 2016 — definitive control; LT4 replacement post-ablation
  3. 3. levothyroxine post-RAI or thyroidectomy
    rxcui 10582
    1.6 µg/kg/d weight-based start; titrate q6-8 wk to TSH • PO • daily
    trigger: post-ablation hypothyroidism
    ATA 2014 hypothyroidism guideline

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: TSH <0.01 + elevated free T4 or T3 + HF symptoms (dyspnea, edema, orthopnea) → thyrotoxic HF pathway; New AFib with rapid ventricular response + features of thyrotoxicosis (heat intolerance, weight loss, tremor, lid lag, exophthalmos) — check TSH urgently; Recent amiodarone exposure or iodinated contrast within 6-8 weeks + new thyrotoxicosis + HF — Jod-Basedow / amiodarone-induced thyrotoxicosis.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Acute HF — thyrotoxicosis-induced (high-output)** (cardio.acute-hf.thyrotoxicosis.v1).
Scope: Thyrotoxicosis-induced high-output HF: TSH suppressed + elevated free T4/T3 + HF symptoms; AFib with RVR common precipitant; consider storm if Burch-Wartofsky ≥45; etiology drives definitive therapy

No severity triggers fired against current inputs.

Plan

Regimen axis: **Thyrotoxicosis-induced high-output HF — BB + thionamide + iodine + steroid (in storm) + supportive HF (ATA 2016 PMID 27521067; JCEM 2023 storm; Klein NEJM 2001)**.
1. propranolol 40 mg PO q4-6h (titrate to HR <100); IV 0.5-1 mg q5min in severe tachycardia (max 5 mg) PO/IV q4-6h titrate (beta_blocker_nonselective, first line) — ATA 2016 — first-line for symptomatic relief + reduces peripheral T4→T3 conversion (unique to nonselective BB at higher doses); PRIMARY benefit even before thionamide takes effect (days-weeks)
2. esmolol 500 µg/kg IV bolus then 50-200 µg/kg/min infusion IV continuous infusion (beta_blocker_short_acting, comorbidity specific) — Titratable IV BB for storm with severe tachycardia or potential decompensation; rapid offset allows reversal if pulmonary edema worsens
3. methimazole 20-30 mg PO daily (single or divided dose); 60-80 mg/d in storm PO daily or BID-TID in storm (thionamide_antithyroid, first line) — ATA 2016 first-line outside pregnancy first trimester due to PTU hepatotoxicity; once-daily dosing improves adherence; longer half-life than PTU
4. propylthiouracil_PTU 100 mg PO q8h (300 mg/d); 200 mg q4h (1200 mg/d) in storm PO q8h or more frequent in storm (thionamide_antithyroid, comorbidity specific) — PTU PREFERRED in first trimester (lower teratogenicity than methimazole) + in storm (more rapidly blocks peripheral T4→T3 conversion); BLACK BOX for hepatotoxicity outside these indications
5. potassium_iodide_lugol_solution Lugol solution 5 drops (250 mg iodine) PO q8h OR SSKI 5 drops PO q8h PO q8h × 7-10 d (iodine_blocking_agent, add on) — ATA 2016 thyroid storm Class I — Wolff-Chaikoff effect blocks hormone release; MUST give ≥1 h AFTER thionamide to prevent escape (substrate for new synthesis); also pre-op prep for thyroidectomy (reduces gland vascularity)
6. hydrocortisone 100 mg IV q8h (300 mg/d total) — also dexamethasone 2 mg IV q6h alternative IV q8h (corticosteroid_glucocorticoid, add on) — ATA 2016 storm Class IIa — reduces peripheral T4→T3 conversion + adrenal support (relative adrenal insufficiency in storm); also primary therapy for amiodarone type 2 thyrotoxicosis (destructive thyroiditis)
7. cholestyramine 4 g PO QID PO QID (bile_acid_sequestrant, add on) — Binds enterohepatic T4 to lower circulating hormone; useful in storm with very high T4 levels; safe + cheap adjunct
8. furosemide 20-40 mg IV (NOT 80-160 — high-output state with often hyperdynamic SVR) titrate to UOP IV q8-12h titrate (loop_diuretic, comorbidity specific) — Standard loop for congestion in HF; gentler dosing in high-output failure (less LV systolic dysfunction; over-diuresis worsens hyperdynamic state)
9. apixaban 5 mg PO BID (2.5 mg BID if 2 of 3 dose-reduction criteria) PO BID (doac_factor_xa_direct, comorbidity specific) — AFib in thyrotoxicosis is independent stroke risk factor; ACC/AHA 2023 (PMID 38033089) — DOAC preferred over warfarin in non-valvular AFib; apixaban favored in elderly per ARISTOTLE
10. digoxin 0.125-0.25 mg PO daily (renal-adjusted; target serum 0.5-0.9 ng/mL) PO daily (cardiac_glycoside, add on) — Add-on rate control if BB insufficient (thyrotoxicosis often resistant to digoxin alone — increased renal clearance + decreased receptor affinity); narrow therapeutic window

Setting playbook (outpatient) — Long-term thyrotoxicosis management with definitive therapy; cardiology surveillance for AFib + HF resolution; ongoing endocrine follow-up; transition off BB when euthyroid sustained
11. maintenance methimazole 5-10 mg/d × 12-18 mo for Graves trial of medical 5-10 mg PO daily PO daily — Graves disease + opted for medical trial (ATA 2016 — 12-18 mo medical trial; ~30-40% remission rate)
12. definitive therapy planning — RAI (I-131) OR thyroidectomy when euthyroid RAI 5-15 mCi (calculated by uptake + gland size) PO single dose — Graves not in remission OR toxic nodular disease OR patient preference (ATA 2016 — definitive control; LT4 replacement post-ablation)
13. levothyroxine post-RAI or thyroidectomy 1.6 µg/kg/d weight-based start; titrate q6-8 wk to TSH PO daily — post-ablation hypothyroidism (ATA 2014 hypothyroidism guideline)

Non-pharmacologic actions:
- Definitive therapy counseling (RAI vs thyroidectomy vs continued medical)
- Cardiac rehab maintenance if persistent HF
- Pregnancy planning counseling (switch to PTU pre-conception if reproductive-age woman)

AVOID / contraindication checks:
- Avoid_aspirin_in_thyrotoxicosis (displaces T4 from TBG → increases free T4 → worsens; use acetaminophen for fever)
- Avoid_iodinated_contrast_in_iodine_induced_thyrotoxicosis (Jod Basedow; further iodine load worsens)
- PTU_only_first_trimester_or_storm_or_methimazole_intolerance (BLACK BOX hepatotoxicity outside these indications)
- Potassium_iodide_must_be_after_thionamide (prevents iodine substrate from being incorporated into new hormone — Wolff Chaikoff escape)
- Avoid_aggressive_cooling_in_storm (vasoconstriction worsens hemodynamics; use cooling blanket + acetaminophen)
- Avoid_haloperidol_in_storm (lowers seizure threshold + neuroleptic syndrome risk; use benzodiazepines for agitation)
- Caution_BB_if_severe_LV_systolic_dysfunction_with_decompensation (use esmolol IV titrate vs propranolol; prepare to reverse if pulmonary edema worsens)
- RAI_contraindicated_in_pregnancy_breastfeeding (use thionamide; RAI fetal harm)
- Thionamide_agranulocytosis_warning_check_CBC_at_any_sore_throat_or_fever (rare ~0.3% but rapid + severe)
- Methimazole_teratogenic_first_trimester (aplasia cutis, esophageal atresia — switch to PTU pre conception)

Monitoring

Regimen monitoring:
- continuous telemetry for AFib or other arrhythmia
- daily BMP LFT CBC during thionamide initiation and storm (agranulocytosis + hepatotoxicity)
- serial free T4 and T3 at 2 4 6 weeks (TSH lags weeks to months after euthyroidism)
- serial HR q1-4h in storm (target HR <100; titrate BB)
- daily burch wartofsky in storm (track resolution; target <25)
- daily temperature for storm and thionamide drug fever
- pre RAI or thyroidectomy thyroid function for euthyroid confirmation
- thyroid US + RAIU when stable to confirm etiology

Setting (outpatient) monitoring:
- Quarterly TFT during med phase
- Annual TFT post-definitive therapy
- Annual echo if HF persisted

Follow-up plan: Endocrinology weekly/biweekly during titration; cardiology for HF management + AFib; definitive therapy planning (RAI vs thyroidectomy vs continued medical for Graves) at 12-18 mo if remission; LFT monitoring weekly × 4 then monthly on PTU; CBC at any infection/sore throat (agranulocytosis); BB withdrawal as euthyroidism achieved + HR normalizes
- Close-out criterion: definitive therapy planned + euthyroid sustained

Monitoring phase: Continuous telemetry + SpO2; serial BMP + LFT + CBC (q24-48h on thionamide); HR + BP + temperature q1-4h; daily Burch-Wartofsky in storm; weekly free T4 + T3 to track response (TSH lags weeks-months); UOP via foley if HF + diuresing; daily exam for thionamide adverse effects (rash, sore throat, jaundice)

Disposition

Current setting: outpatient — Long-term thyrotoxicosis management with definitive therapy; cardiology surveillance for AFib + HF resolution; ongoing endocrine follow-up; transition off BB when euthyroid sustained

Disposition criteria:
- Long-term continuation; if Graves remission sustained 1 yr off meds → discharge to PCP; if definitive therapy → lifelong levothyroxine + annual TSH

Escalation triggers (move to higher acuity):
- Recurrent thyrotoxicosis → consider definitive therapy
- New AFib episode → cardiology re-evaluation
- Pregnancy → switch methimazole to PTU first-tri
- Hypothyroid post-ablation → start levothyroxine

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Burch-Wartofsky Point Scale ≥45 — fever (>38.9), CNS (agitation/AMS), GI (vomiting/diarrhea/jaundice), HR >130, HF (CHF/Killip), precipitating event present — life-threatening decompensation
- [SEVERE] New AFib with rapid ventricular response (HR >120) + features of thyrotoxic HF (pulmonary edema, peripheral edema, NYHA III-IV) — common decompensation pattern in thyrotoxicosis
- [SEVERE] LFT elevation >3x baseline OR jaundice in patient on PTU therapy — BLACK BOX warning

Citations

- ATA 2016 thyrotoxicosis (Ross PMID 27521067) + JCEM 2023 thyroid storm + 2022 ACC/AHA HF + 2023 ACC/AHA AFib [PMID:27521067](https://pubmed.ncbi.nlm.nih.gov/27521067/)
- Cited evidence (PMID 11172193) [PMID:11172193](https://pubmed.ncbi.nlm.nih.gov/11172193/)
- Cited evidence (PMID 20639554) [PMID:20639554](https://pubmed.ncbi.nlm.nih.gov/20639554/)
- Cited evidence (PMID 15817880) [PMID:15817880](https://pubmed.ncbi.nlm.nih.gov/15817880/)
- Cited evidence (PMID 35363499) [PMID:35363499](https://pubmed.ncbi.nlm.nih.gov/35363499/)

Last reconciled with current guidelines: 2026-05-15.
References